Caliway Advances Global Phase 3 Program for CBL-514
New Taipei City, Taiwan – May 22, 2026 Caliway Biopharmaceuticals has announced a major milestone for its innovative injectable...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
New Taipei City, Taiwan – May 22, 2026 Caliway Biopharmaceuticals has announced a major milestone for its innovative injectable...
